Search for: "BRISTOL-MYERS SQUIBB"
Results 481 - 500
of 866
Sorted by Relevance
|
Sort by Date
7 Feb 2010, 11:28 pm
See Bristol-Myers Squibb Co. v. [read post]
25 Apr 2007, 5:43 pm
Following Bristol-Myers Squibb Co. v. [read post]
16 May 2008, 7:30 am
The focus of this FDA investigation was the possible increased risk of death associated with Maxipime, which is an injectable antibiotic that is manufactured by Bristol-Myers Squibb Co. [read post]
23 Feb 2009, 1:44 am
The commercials for Bristol-Myers Squibb's (BMS) new Rheumatoid Arthritis Drug, Orencia (c). [read post]
17 Apr 2009, 11:05 am
Such arrangements aren’t unprecedented, though: In 2007, AstraZeneca PLC and Bristol-Myers Squibb Co. struck a partnership to develop and market two diabetes drugs. [read post]
9 Jun 2009, 9:05 am
Bodnar, a former senior vice president at Bristol-Myers Squibb, had pleaded guilty to making a false statement to the federal government about the company's efforts to resolve a patent dispute over the blood thinner Plavix. [read post]
21 Apr 2023, 9:27 am
Apr. 19, 2023) In 2019, Amgen acquired worldwide rights to apremilast (OTEZLA) from Celgene $13.4 billion in cash, in connection with Celgene’s merger with Bristol-Myers Squibb. [read post]
20 Sep 2017, 9:18 am
In Bristol-Myers Squibb Co. v. [read post]
30 Aug 2021, 12:27 pm
The proper jurisdiction for these suits, as the Seyfarth post notes, became open to debate after a US Supreme Court 2017 decision in Bristol Myers Squibb v Superior Court. [read post]
26 May 2007, 11:26 pm
Bristol-Myers Squibb and Sa nofi-Aventis, which co-market the widely used drug, defended the patent from a challenge by Canadian generic drugmaker Apotex, which briefly flooded the market with copycat Plavix tablets last summer. [read post]
30 Oct 2013, 2:08 pm
In reviewing the current Bristol-Myers Squibb/Sanofi Pharmaceuticals Plavix Prescribing Information (label revised 9/23/13; accessed 10/30/13), however, there is no mention of hemophilia (nor haemophilia) in that document. [read post]
21 Oct 2014, 9:03 am
In Bristol-Myers Squibb Company v. [read post]
7 Apr 2010, 4:37 pm
In June 2005, the feds in New Jersey indicted Frederick Schiff, the CFO of Bristol-Myers Squibb, for failing to disclose material facts to investors. [read post]
16 Feb 2011, 12:04 am
It looks like they would also do away with all the problems of the “threshold” requirement introduced by Phillips v Mirabella (the nature of the problem is laid out at paragraphs 19 to 27 of Bristol-Myers Squibb v Faulding). [read post]
28 Sep 2010, 3:14 pm
Par Pharmaceutical Companies, Inc. et al (Patent Docs) Baraclude (Entecavir) – US: Patent infringement complaint filed following Paragraph IV certification: Bristol-Myers Squibb Co. v. [read post]
13 Feb 2015, 12:00 pm
At issue in the case were Bristol-Myers Squibb’s anticoagulant Coumadin and AstraZeneca’s ulcer drugs Prilosec and Nexium. [read post]
15 Apr 2010, 4:27 am
(EPLAW) Prevacid (Lansoprazole) – US: Takeda files patent infringement complaint against Zydus following Para IV challenge (Patent Docs) Reyataz (Atazanavir) – US: Bristol-Myer Squibb, Novartis file patent infringement suit against Teva following Para IV challenge (Patent Docs) Treximet (Sumatriptan, Naproxen) – US: POZEN enters into settlement agreement with Teva regarding Para IV patent litigation (SmartBrief) Zerit (Stavudine) – US: Promote… [read post]
19 Oct 2011, 2:30 pm
Bristol-Myers Squibb and Sanofi-Aventis are arguing that centralizing the cases before Judge Freda Wolfson in the U.S. [read post]
19 Mar 2010, 7:45 am
If Bristol-Myers Squibb and Sanofi-Aventis knew of these problems and did not warn doctors and patients appropriately, they could be held responsible for harm suffered by patients who took their drug. [read post]
28 Aug 2018, 12:16 am
Although fact-specific, this case sets a threshold as to actions which would not constitute the repackaging of products (whilst Bristol-Myers Squibb and Boehringer Ingelheim set out actions which would). [read post]
